5-Amino-1MQ
INVESTIGATIONALNNMT inhibitor | Fat loss (oral)
Updated: August 2026.
Key points
- What it is: small-molecule inhibitor of the NNMT enzyme (nicotinamide N-methyltransferase).
- Main use: fat loss and metabolic health.
- Typical dose: 50–150 mg once a day, orally.
- Key result: by inhibiting NNMT in fat cells, it raises NAD+ and cellular metabolism.
- Common effects: poorly characterized; generally mild (research compound).
- Comparison: acts through a different pathway from GLP-1s; oral, not injectable.
- Status: not FDA-approved (research compound).
Overview
What is 5-Amino-1MQ?
5-Amino-1MQ is a small molecule that inhibits the NNMT enzyme (nicotinamide N-methyltransferase), which is highly active in fat tissue. It is researched for its ability to reactivate adipocyte metabolism and promote fat loss without being a hormonal agonist like the GLP-1s.
Key benefits
By slowing NNMT, available cellular NAD+ rises and fat-tissue energy expenditure is stimulated. In preclinical models it is associated with reduced fat and better metabolic function, with the convenience of the oral route.
Mechanism of action
NNMT consumes NAD+ and slows adipocyte metabolism. By inhibiting it, 5-Amino-1MQ raises NAD+, reactivates lipolysis and may reduce fat-cell size. This is a metabolic mechanism, not hormonal appetite suppression.
Quick start guide
Dosing protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Standard | 50–150 mg | 1 time/day (oral) | 8–12 weeks |
Oral route. Start at the low dose. As a research compound, dosing data are limited: the regimen must be assessed by a healthcare professional.
🧮 Calculate your exact syringe dose →⚠️ Who should NOT use it
- Limited safety data as it is a research compound.
- Pregnancy or breastfeeding.
- People with liver or kidney disease — consult first.
- Always under the supervision of a healthcare professional.
What to expect
- Week 1-2: no noticeable changes; the effect is metabolic and gradual.
- Week 2-4: possible improvement in energy.
- Week 4-8: body-composition changes in some users.
- Week 8-12: expected peak effect of the cycle.
- Side effects: poorly characterized; generally mild.
- Most effective for: fat loss as support for diet and exercise.
Side effects & safety
- Poorly characterized effect profile (research compound).
- Possible mild digestive discomfort.
- Transient headache or energy changes.
- Poorly defined interactions: caution with other medications.
- Start at a low dose to assess tolerance.
- Allergic reaction: rash, itching or swelling.
- Severe or persistent digestive discomfort.
- Any unexpected, striking symptom.
- Signs of a liver problem (jaundice, pain).
- If you are pregnant or planning a pregnancy.
Frequently asked questions
What is 5-Amino-1MQ?
It is a small molecule that inhibits the NNMT enzyme and is researched for fat loss and metabolic health.
How does 5-Amino-1MQ work?
It blocks NNMT in fat cells, which raises NAD+ and reactivates metabolism, potentially reducing fat-cell size.
Is 5-Amino-1MQ injected?
No; it is usually taken orally, which sets it apart from injectable weight peptides.
What is the usual dose?
Around 50-150 mg per day orally (investigational). The regimen must be assessed by a professional.
What are the side effects?
They are poorly characterized as it is a research compound; generally described as mild.
Is 5-Amino-1MQ approved?
No; it is a research compound not approved by the FDA.
Research areas
- Fat loss
- Cellular metabolism
- NAD+ increase
- Metabolic health
- Longevity
Related peptides
- AOD-9604 — hGH fragment focused on fat burning.
- MOTS-c — Mitochondrial peptide for metabolism and energy.
- Tesamorelin — GHRH analog for visceral fat.
Related articles
Related topics
- 5-Amino-1MQ and NNMT
- 5-Amino-1MQ dose
- 5-Amino-1MQ fat loss
- 5-Amino-1MQ and NAD+
- 5-Amino-1MQ oral
- 5-Amino-1MQ side effects
Summary
What it is: Oral inhibitor of the NNMT enzyme.
How it is researched: Oral, 50-150 mg once a day.
Key features: Raises NAD+ and fat metabolism. Not FDA-approved.
Related peptides: AOD-9604, MOTS-c and Tesamorelin.